Skip to main content
. Author manuscript; available in PMC: 2012 Sep 1.
Published in final edited form as: Pediatr Blood Cancer. 2011 Jun 16;57(3):398–405. doi: 10.1002/pbc.22966

Figure 3.

Figure 3

Actuarial disease-free survival of Interleukin-2 group and control group according to Phase 2 randomization to IDADCTER (idarubicin, cytarabine, thioguanine, etoposide, and daunorubicin) and FLU IDA (fludarabine monophosphate, cytarabine and idarubicin)